4D Molecular Therapeutics (FDMT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$1.02
- Surprise
- —
- Revenue (period 2026-06-30)
- $3.8M
- Score today
- 5.2/10
Revenue source: xbrl.
Where TrendMatrix's rating stands now
TrendMatrix currently rates FDMT Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-10.
What argues against it
- Quality below floor (2.5 < 4.0)
- Momentum score 3.3/10 — below 4.5 minimum
- Insider activity: 0.43%=heavy
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.56
- Price target
- $24.52
- Stop
- $11.93
- Upside to target
- +95.2%
- Reward-to-risk
- 6.3:1
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
FDMT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $713.8M
- P/E (fwd)
- -3.2
- 52-week range
- $6.96–$16.93
- Off 52-week high
- 25.8%
- RSI (14)
- 39
- Volume vs avg
- 1.09×
- Score today
- 5.2/10